Data layers Raw facts Calculated Model prediction AI interpretation

Company Overview

Stock NameHua Medicine-B
Stock Code02552
Company Full NameTo be extracted
IndustryHealthcare
Principal Activities華領醫藥是一家中國藥物開發公司,目前致力於開發用於治療2型糖尿病的全球首創口服新藥Dorzagliatin或HMS5552。
Listing Date2018-09-14
Listing Rules EraOld Rules
Listing Rules Chapter18A生物科技
Weighted Voting Rights (WVR)No
Registered Address (Mainland China)中國上海市愛迪生路275號華領醫藥(郵編:201203)
Business Address (Hong Kong)香港灣仔軒尼詩道36號循道衛理大廈2202室
Place of IncorporationTo be extracted
Listing MethodTo be extracted
Listing BoardMain Board
Websitewww.huamedicine.com
Share Registrar卓佳证券登记有限公司 (Tricor Investor Services Limited)
Registrar Contact(852)2980 1333
A-Share/US Dual ListingNo

Offering Information

Offering Mechanism Mechanism A
Offer PriceHK$ 8.28 / shares
Offer Price RangeTo be extracted
Lot Size500 shares
Entry ThresholdTo be extracted
Par ValueRMB 0.001 / shares
Offer Period2018-08-31 to 2018-09-05
Global Offering Shares104,756,000 shares
HK Public Offer Shares (Initial)10,476,000 shares (10.0%)
Public Offer Lots (Initial)20,952lots (Pool A10,476lots,Pool B10,476lots)
International Placing Shares (Initial)94,280,000 shares (90.0%)
Offer Ratio~10.0%
Total Shares Post-IPO1,051,913,300 shares
Greenshoe (Over-allotment Option)No
Stabilizing Manager (Greenshoe)—
Cornerstone ShareNo cornerstone investors
Clawback TiersTo be extracted
Reallocation OptionYes
Total Global Offering SizeHK$ 867,379,680

Stock Connect Inclusion Analysis

26Q4 Regular Review
Inclusion Pathway Regular Path
Avg Daily HK Mkt Cap HK$ 2.83B
Est. Threshold HK$ 9.71B
Analysis Result HK market cap below threshold, need +244%

Valuation & Financials

Market Cap (at Offer Price)HK$ 9,235,798,774
Pre-IPO Valuation (Last Round)Not disclosed
P/E Ratio不適用(公司處於虧損狀態)
Profit/Loss Status虧損人民幣280.7百萬元
Period-End Cash Balance人民幣172.7百萬元
Listing Expenses~HK$ 89,057,680
Listing Expenses / Funds Raised~10.27%
Total Pre-IPO Investment210.5百萬美元

Financial Data

Unit: '000 RMB
Income Statement
Item 201620172018-03
Other income and gains, net 1,03011,7066,110
Administrative expenses -19,482-31,086-13,725
Net finance costs -4,562-2,958-4,500
Profit before tax -362,408-280,688-322,322
Income tax expense 000
Profit for the year -362,408-280,688-322,322
Profit attributable to owners -361,328-272,714-321,053
Balance Sheet
Item 201620172018-03
Cash and cash equivalents 192,901172,733836,064
Total current assets 224,541232,288906,533
Total current liabilities 25,28142,99749,295
Total equity -666,196-942,530-1,259,854
Equity attributable to owners -670,142-953,880-1,262,762
Cash Flow Statement
Item 201620172018-03
Net cash from operating activities -76,051-198,694-66,085
Net cash from investing activities -29,24114,475-112
Net cash from financing activities 151,259172,904738,470
Net increase in cash 55,292-20,168663,331
Depreciation of PP&E 361637241
Purchase of PP&E -647-2,419-418
Income Statement
Balance Sheet
Cash Flow Statement
Source: Accountants' Report and Audited Consolidated Financial Statements
First Day CloseHK$ 8.28
First Day OpenHK$ 8.28
First Day Change-55.80%
First Day Volume11815000.0
First Day Turnover96901900.0
Use of Proceeds
1、約39%(或304.4百萬港元)將用于在未來兩年內完成Dorzagliatin進行III期試驗, 其中約35%分配至單藥治療試驗,而65%則分配至與二甲雙胍聯合療法試驗; 2、約9%(或70.3百萬港元)將用于在未來三年內涉及Dorzagliatin的進一步研發,將包括聯用試驗; 3、約27%(或210.8百萬港元)將用于在未來三年內在中國推出Dorzagliatin及商業 化,包括營銷、銷售及生產; 4、約11%(或85.9百萬港元)將用于在未來三年內進一步研究涉及Dorzagliatin的固 定劑量組合及個人化糖尿病以及mGLUR5的研究; 5、約4%(或31.2百萬港元)將用于在未來三年內開拓直接與糖尿病或我們認為重大醫 療需求而未被滿足的新治療領域有關的其他特許及合伙商機; 6、約10%(或78.1百萬港元)將用作我們的一般公司及營運資金用途。

Underwriting Syndicate

Joint Sponsors (2)
GOLDMAN SACHS (ASIA) L.L.C. CE ACC536 CITIC Securities (Hong Kong) Limited CE AAK249
Overall Coordinators (3)
GOLDMAN SACHS (ASIA) L.L.C. CE ACC536 CLSA LIMITED CE AAB893 UBS Securities Hong Kong Limited CE BIN466
Joint Bookrunners (3)
GOLDMAN SACHS (ASIA) L.L.C. CE ACC536 CLSA LIMITED CE AAB893 UBS Securities Hong Kong Limited CE BIN466
Joint Lead Managers (4)
GOLDMAN SACHS (ASIA) L.L.C. CE ACC536 CLSA LIMITED CE AAB893 UBS Securities Hong Kong Limited CE BIN466 国泰君安证券(香港)有限公司 CE ABY236

Cornerstone Investors

This stock has no cornerstone investors.

Directors & Management

PositionChinese nameEnglish Name
Chairman陳力—
Company Secretary鄭杏怡—
No director data available.

Major Shareholders

Major Shareholders & Holdings主要股東包括ARCH Venture Fund VII, L.P.(約11.89%)、The Core Trust Company Limited(約11.12%)、FIL Limited(約10.24%)、FMR LLC(約10.04%)等。本公司並無控股股東。
About this page

This page shows Hua Medicine-B (02552) prospectus details: offer price range, fundraise size, cornerstone investors, greenshoe, Pool A/B allocation and syndicate. For eligible IPOs it also provides a Stock Connect inclusion analysis, indicating the pathway and estimated timing for Southbound Connect admission; for A-share / US secondary listings, it additionally compares the other market's price, exchange rate and the H-share premium/discount. Data is parsed from the HKEX prospectus and related announcements. New to IPO subscription? See Hong Kong IPO Subscription 101.

Cibo — HK IPO Allotment Forecasts, Allottee Profiling & Stock Connect